EUCTR2020-000775-20-DE进行中（未招募）1 期
A phase II study evaluating reduced starting dose and dose escalation of Cabozantinib as second-line therapy for advanced HCC in patients with preserved liver function
Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest0 个研究点目标入组 40 人开始时间: 2020年4月27日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Fully-informed written consent.
- •2.Males and females = 18 years of age.
- •*There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently.
- •3.Patients with HCC who have been previously treated with any first line therapy.
- •4.Locally advanced or metastatic and/or unresectable HCC with preserved liver function (Child-Pugh A only, if liver cirrhosis is present) with diagnosis confirmed by histology/cytology or clinically by guideline criteria.
- •5.Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
- •6. Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade 1 prior to study entry, with the exception of alopecia.
- •7. ECOG performance status = 2.
- •8.Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.
- •9.For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods from the time of signing the informed consent through at least 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.
- •Male patients, even if surgically sterilized (i.e. status post-vasectomy) must agree to practice effective barrier contraception (e.g. condom) and to refrain from sperm donation during the entire study treatment period and through at least 4 months after the last dose of study drug or agree to completely abstain from heterosexual intercourse.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1.Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 4 months.
- •2.Significant portal hypertension (moderate or severe ascites). Significant hypertension, defined as blood pressure = 140 mmHg (systolic) or = 90 mmHg (diastolic) in repeated measurements.
- •3.Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
- •4.Patients with impaired liver function defined as Child-Pugh B or C, if liver cirrhosis is present.
- •5.Severely impaired kindey function (defined as creatinine > 2mg/dl and/or creatinine clearance < 45 ml/min).
- •6. Elevations of AST/ALT > 5 x ULN at baseline.
- •7.Presence of encephalopathy in past 12 months.
- •8.Significant cardiovascular disease (such as NYHA Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.
- •9.Baseline QTcF > 500 ms.
- •10.Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study.
- •11.Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.
- •12.Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.
- •13.Treatment with investigational systemic therapy within 28 days
- •or five times the elimination half-life of the investigational product, whichever is longer, prior to initiation of study treatment.
- •14.Prior cabozantinib use.
- •15.Known or suspected hypersensitivity to cabozantinib or any other excipients of the IMP.
- •16. Rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
- •17. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
- •18.Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
- •19.Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
研究者
相似试验
招募中
不适用
A phase II study of the dose reduction and shortening of duration of immunosuppressant after HLA-haploidentical transplantation with post-transplantation cyclophosphamide following reduced-intensity conditioninghematologic malignanciesJPRN-UMIN000026002JSCT55
招募中
不适用
A phase II study of the dose reduction and shortening of duration of immunosuppressant after HLA-haploloidentical transplantation with post-transplantation cyclophosphamide following myeloablative conditioninghematologic malignanciesJPRN-UMIN000026001JSCT42
招募中
1 期
A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide, dexamethasone and nirogacestat in patients with transplant ineligible newly diagnosed multiple myelomaewly diagnosed patients with multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2022-001942-39-GRHellenic Society of Hematology (EAE)36
进行中（未招募）
1 期
Belantamab Mafodotin in combination with Lenalidomide and Dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who transplant ineligible.EUCTR2020-005826-27-GRHellenic Society of Hematology (EAE)66
进行中（未招募）
1 期
Belantamab Mafodotin in combination with Daratumumab, Lenalidomide and Dexamethasone for the treatment of patients with newly diagnosed multiple myeloma transplant ineligible.newly diagnosed multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2021-006792-42-GRHellenic Society of Hematology (EAE)36